Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma.
Abstract
<h4>Background</h4>Pemigatinib is an inhibitor of the fibroblast growth factor receptor
(FGFR), recently approved for the treatment of cholangiocarcinoma. FGFR retinopathy
is a newly recognized entity, with only two other FGFR inhibitors reported to cause
serous retinopathy. Herein, we describe the first published report of a multifocal
serous retinopathy secondary to pemigatinib.<h4>Case presentation</h4>A 67-year-old
male with stage 4A metastatic colon adenocarcinoma undergoing systemic therapy with
pemigatinib was found to have developed bilateral multifocal serous retinopathy. Fundus
autofluorescence showed corresponding multifocal hypoautofluorescent foci, whereas
fluorescein angiography and indocyanine green angiography were unremarkable. Subretinal
fluid resolved rapidly after discontinuation of pemigatinib.<h4>Conclusions</h4>Multifocal
serous retinopathy appears to be a class effect of FGFR inhibitors. FGFR retinopathy
clinically resembles MEK retinopathy-both feature multifocal subretinal fluid, low
visual significance, and quick resolution. However, given that FGFR inhibitors have
a broader molecular range than MEK inhibitors, further characterization of FGFR retinopathy
is necessary to generate management guidelines.
Type
Journal articlePermalink
https://hdl.handle.net/10161/26128Published Version (Please cite this version)
10.1186/s40942-021-00305-9Publication Info
Alekseev, Oleg; Ojuok, Effy; & Cousins, Scott (2021). Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma.
International journal of retina and vitreous, 7(1). pp. 34. 10.1186/s40942-021-00305-9. Retrieved from https://hdl.handle.net/10161/26128.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Oleg Alekseev
Medical Instructor in the Department of Ophthalmology
Dr. Alekseev completed combined MD-PhD training at Drexel University College of Medicine
and pursued post-doctoral fellowship training at the University of Pennsylvania School
of Medicine. He completed Ophthalmology residency training at the University of North
Carolina School of Medicine, where he also served as a chief resident. Dr. Alekseev
pursued double-fellowship training in Medical Retina and Inherited Retinal Degenerations
at the Duke Eye Center, where he then joined the f
Scott William Cousins
Robert Machemer, M.D. Distinguished Professor of Ophthalmology
Scott W. Cousins, M.D. is currently the Robert Machemer, M.D. Professor of Ophthalmology
and Immunology, Vice Chair for Research, and Director of the Duke Center for Macular
Diseases at Duke Eye Center. As Vice Chair, he oversees all basic science research
as well as the Ophthalmology Site-Based Research Group, which administrates clinical
research for Duke Eye Center. Dr. Cousins is also Medical Director of Hospital-Based
Imaging and Procedures for Duke Eye Center. Dr. Cousins is a
Alphabetical list of authors with Scholars@Duke profiles.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info